Applied Biology Division, CSIR-Indian Institute of Chemical Technology, Hyderabad, 500007, Telangana, India.
School of Nano Sciences, Central University of Gujarat, Gandhinagar, 382030, Gujarat, India.
Int J Biochem Cell Biol. 2019 Sep;114:105567. doi: 10.1016/j.biocel.2019.105567. Epub 2019 Jul 8.
The biggest challenge in delivering anticancer agents is the ability to direct these molecules specifically to cancer cells. With this in mind, modern research is focussing on improving the precision of cancer drug delivery by incorporating a ligand that has the ability to specifically recognize cancer cells. Peptides are emerging as a new tool in drug and gene delivery. Peptide-drug conjugates, peptide-modified drug delivery systems, and peptide-coupled imaging agents have been shown to increase on-site delivery. This has allowed better tumor mass contouring in imaging and increased therapeutic efficacy of chemotherapies, reducing adverse effects. Benefits of peptide ligands include their small size, easy and affordable production, high specificity and remarkable flexibility regarding their sequence and conjugation possibilities. Bombesin (Bn) receptors have shown great promise for tumor targeting due to their increased expression in a variety of human cancers, including prostate, breast, small cell lung, and pancreatic cells. This review discusses the overexpression of Bn receptors in different cancers and various approaches to target these receptors for therapeutic and diagnostic interventions in human malignancies.
将抗癌药物递送到体内的最大挑战在于能够将这些分子特异性地递送到癌细胞。有鉴于此，现代研究正专注于通过结合能够特异性识别癌细胞的配体来提高癌症药物递送的精确性。肽类正在成为药物和基因递送的新工具。肽-药物偶联物、肽修饰的药物递送系统和肽偶联的成像剂已被证明可以增加局部递药。这使得在成像中更好地勾勒肿瘤质量，并提高化疗的治疗效果，减少不良反应。肽配体的优点包括其体积小、易于生产且成本低、特异性高以及在序列和缀合可能性方面具有显著的灵活性。蛙皮素 (Bn) 受体由于在多种人类癌症（包括前列腺癌、乳腺癌、小细胞肺癌和胰腺癌）中表达增加，因此在肿瘤靶向方面显示出巨大的潜力。本综述讨论了 Bn 受体在不同癌症中的过表达以及针对这些受体的各种方法，以用于人类恶性肿瘤的治疗和诊断干预。
